In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals
about
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmissionPrimaquine or other 8-aminoquinoline for reducing P. falciparum transmissionPrimaquine for reducing Plasmodium falciparum transmissionMass drug administration for malariaPrimaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquineRationale for short course primaquine in Africa to interrupt malaria transmissionReview of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop reportPrimaquine radical cure of Plasmodium vivax: a critical review of the literatureSustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytesA head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trialThe potential contribution of mass treatment to the control of Plasmodium falciparum malariaG6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based mapGlucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort StudySerological evidence of discrete spatial clusters of Plasmodium falciparum parasitesSingle dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.A research agenda for malaria eradication: diagnoses and diagnosticsGlucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine.Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screeningEffectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationThe effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial.Primaquine: the risks and the benefitsGenetic determinants of glucose-6-phosphate dehydrogenase activity in KenyaOperational strategies to achieve and maintain malaria elimination.Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia.The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trialA cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy.Confirmed Plasmodium vivax Resistance to Chloroquine in Central VietnamA novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency.Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in InfantsTolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of ageSingle low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.PharmGKB summary: very important pharmacogene information for G6PD.The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector.Modelling the therapeutic dose range of single low dose primaquine to reduce malaria transmission through age-based dosing.Prevalence and molecular characterization of G6PD deficiency in two Plasmodium vivax endemic areas in Venezuela: predominance of the African A-(202A/376G) variant.Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda.
P2860
Q24188070-65F378C2-A81B-4E35-8866-C3B194BFD076Q24193716-578B409B-CFDA-4201-B44F-355A4D8E4EA2Q24200471-E8FF8C12-4AF5-4978-84C5-49078C2478B2Q24201881-A3657C22-757C-4073-B601-2B3167A843FDQ24202900-22AA3CE4-3198-494E-8EAC-E71494D72C97Q27006552-4150FAE0-4089-4230-A107-2FAE418B6D58Q27024922-522E5DC6-5664-4C00-BC39-12EED250C340Q27027939-C79063D6-5A84-4244-BF2D-1FAE915DB28FQ28125936-CA297916-996E-411C-95C3-D94CFBDAE3B6Q28477853-FB8C0DCA-1584-4AE0-A223-2341447BCF4CQ28478260-D8BC1F12-B588-4507-AF98-541A7D2D9AEDQ28485156-E94E1F77-C076-450D-866F-B1ED93CEB76CQ28547654-0BA5333B-D321-4F68-821D-2022EF3AB013Q28743081-D5DF8CED-1808-4CB0-B52E-0E6E4355F9AEQ33772980-01EC3CAC-2B33-45A3-9C12-DAC7B2D231EAQ33818031-4007FBEE-B4FD-418F-B508-9835FA7F3D34Q34058341-56717FF5-60CA-442F-8344-72AD55468157Q34099217-191F0E34-8FCB-4833-B95F-77E4F5E0E4C4Q34164652-9EADA555-E0FF-4D52-A36F-A93F4DA007B6Q34177472-954284BD-1E9D-4880-BE7E-B39A4F78A608Q34486508-544F32CE-0AB7-454B-B8AF-A7F3696B019FQ34503631-EFD9C2A3-532F-4B8D-87F1-F28796D6336EQ34538235-92E393DD-FDE6-49B0-835E-2A12AEF3651DQ34568019-1B5A4403-D6F5-4BF2-BDA7-8BF2C6F994FEQ34777088-CF045893-4404-4F5A-A0B5-91C277E74017Q35147721-CA7C2408-4E09-49C6-A346-5D9EFDE0C106Q35203887-61ECF304-CC07-435B-A3A7-F53ED9CB6A25Q35270733-B53CC112-25F5-4E7E-83E0-254DDF8D9227Q35782842-7A7D1113-083A-4ECB-AA25-1C7EDADC6F52Q35800621-714D0D37-EDB4-4DF8-8F51-3274BBE2C6EAQ35850290-52420AD5-C4EC-45FE-986D-820BE018EDA5Q35867507-3745EA64-129C-4141-A4F1-3B7E54A08E14Q35948587-6FEA5D8A-B144-41C2-AA8B-C418ABB43E60Q36055205-2976DF28-3E0A-495E-8DDA-BBA54F96C0B5Q36086489-D059787C-E290-4F8C-A8D8-980299C427FEQ36340896-7C1E1A5A-B570-4DAE-8D12-91D8A4264DA2Q36454688-27893AFF-6C04-4433-970D-922389C447ABQ36538990-45B8149F-35A9-4638-94A8-5322D0BEC7F3Q36617963-6B33E1D7-F136-4D89-BDA8-3EA2F90CFB6AQ36730218-5E019D03-B0A7-4646-B64E-A2BB546D2675
P2860
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@ast
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@en
type
label
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@ast
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@en
prefLabel
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@ast
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@en
P2093
P2860
P50
P356
P1476
In Tanzania, hemolysis after a ...... eficient (G6PD A-) individuals
@en
P2093
Adrian J F Luty
Jan B Koenderink
Modibo Daou
Reginald Kavishe
Roel ter Braak
Seif A Shekalaghe
Wouter van den Bijllaardt
P2860
P304
P356
10.1128/AAC.01135-09
P407
P577
2010-03-01T00:00:00Z